SCIENCE
Next Generation Immunotherapy
We are developing T-sphaera with immune cell engaging function that has higher antigen binding ability,
and broader expandability compared to antibody treatments.
T-sphaera is a novel class of protein with higher antigen binding ability,
easy synthesis and broad expandability that can replace conventional antibodies.
easy synthesis and broad expandability that can replace conventional antibodies.
Antigen Binding Ability Study
Superior target-binding ability compared to monoclonal antibody
& diverse target-binding capability
& diverse target-binding capability
Immune Cell Engager
PD-L1 x TIGIT Bispecific T-sphaera
PD-L1 Antibody
Time: 24 h, Human cancer cell: 104 cells
PBMC: 105 cells, Cell ratio: 1:10, Concentration: 500 nM
PBMC: 105 cells, Cell ratio: 1:10, Concentration: 500 nM
Superior anti-cancer efficacy compared to monoclonal antibody